Trial Profile
Phase II study of pre-operative treatment with external radiotherapy plus panitumumab in operable locally advanced rectal cancer (favourable and intermediate prognostic group) (RaP Study/STAR-03)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2019
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms RaP/STAR-03
- 15 Feb 2018 Status changed from recruiting to completed.
- 02 Jun 2015 According to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology, 67 patients has been enrolled till Jan 2015.
- 02 Jun 2015 Interim results (n=55) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.